Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Cellzome Gets Another Investment From GSK

by Michael McCoy
March 15, 2010 | A version of this story appeared in Volume 88, Issue 11

Cellzome has formed a drug discovery alliance with GlaxoSmithKline involving epigenetics related to inflammatory disease. Under the deal, Cellzome will receive $45 million up front and could reap more than $650 million in milestone payments. GSK will get access to Episphere, Cellzome’s chemical proteomics technology for the discovery of small-molecule drugs directed at targets involved in epigenetic regulation. Cellzome received $22 million from GSK in September 2008 in a deal involving kinase-targeted therapeutics.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.